Oxford Nanopore Technologies, a Genomics Unicorn Backed by CCB International, Lists on London Stock Exchange

Recently, UK unicorn and DNA sequencing company Oxford Nanopore Technologies listed on the London Stock Exchange, attracting strong investor interest. With a total market capitalization approaching $7 billion, it has become one of the most highly valued tech companies in the UK.

Originating from the University of Oxford in the United Kingdom, the company was formally established in 2005 and is dedicated to developing breakthrough electronic single-molecule sensing systems based on nanopore science. Nanopore sequencing technology, also known as fourth-generation sequencing, is a new generation of sequencing technologies that has emerged in recent years. It is characterized by single-molecule sequencing, long read lengths (exceeding 150 kb), high sequencing speed, real-time data monitoring, and portability of the devices. As a pioneer in this field, Oxford Nanopore Technologies launched its first sequencer, MinION, in 2015. Owing to its rapid and real-time capabilities, the product has served customers in over 100 countries and is applied in areas such as healthcare, agriculture, and environmental monitoring.

In recent years, the company has achieved rapid development. According to its prospectus, its sales have expanded globally, with continuous growth in both customer base and revenue scale. The company is set to launch multiple new products in the near future, further advancing automation, high accuracy, high throughput, and AI-enabled data reading capabilities, thereby enhancing product performance and broadening applicability across more scenarios. As a pioneer in fourth-generation nanopore DNA sequencers, the company will lead breakthroughs and upgrades in the global sequencing technology industry. In 2020, the company’s revenue reached £114 million, more than doubling compared to 2019.

Prominent Chinese institutions such as CCB International invested in Oxford Nanopore Technologies in 2018. Other notable investors included U.S.-based Amgen and the Abu Dhabi Technology Development Committee (TDC), boasting a prestigious lineup of institutional investors.

Oxford Nanopore Technologies has established robust partnerships with numerous Chinese technology enterprises and research institutions, making significant contributions to the advancement of China’s healthcare and technology services sectors. At the onset of the pandemic in 2020, facilitated by the active promotion of CCB International, Oxford Nanopore collaborated with the Chinese Center for Disease Control and Prevention (China CDC) on COVID-19 containment efforts. Prioritizing viral genome decoding as a top global initiative, the company provided the national CDC with novel viral sequencing solutions, the latest-generation sequencers, customized products, and dedicated 24/7 technical support. This enabled rapid decoding of viral sequences, laying a solid foundation for the development of COVID-19 vaccines and therapeutics.

As a pioneer in nanopore sequencing, Oxford Nanopore Technologies has successfully listed on the London Stock Exchange. The company stated that its unique sequencing technology will drive further research discoveries and, potentially through integration with technologies such as wearable devices, create new fields and transformative changes. Oxford Nanopore Technologies has deep ties with China, having received support from prominent Chinese investment institutions such as CCB International. Its globally leading gene sequencing technology has also facilitated the development of China’s medical and scientific research services, thereby expanding high-level technological cooperation between China and the United Kingdom.